IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have received an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $747.00.

A number of brokerages have recently issued reports on IDXX. Citigroup lifted their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Barclays reduced their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. UBS Group lifted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th.

Hedge Funds Weigh In On IDEXX Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of IDXX. Saudi Central Bank lifted its stake in IDEXX Laboratories by 88.7% in the 2nd quarter. Saudi Central Bank now owns 5,560 shares of the company’s stock worth $2,927,000 after purchasing an additional 2,613 shares in the last quarter. AlphaGrep UK Ltd purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $1,385,000. Maloon Powers Pitre Higgins & Dennehy LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $303,000. Plan A Wealth LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $203,000. Finally, SVRN Asset Management LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $290,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 2.0%

Shares of IDEXX Laboratories stock opened at $556.93 on Friday. The firm has a market capitalization of $43.87 billion, a PE ratio of 39.17, a P/E/G ratio of 2.97 and a beta of 1.54. IDEXX Laboratories has a twelve month low of $518.55 and a twelve month high of $769.98. The firm’s 50-day moving average price is $560.01 and its 200 day moving average price is $576.88. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same period in the previous year, the firm posted $3.50 EPS. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts predict that IDEXX Laboratories will post 14.81 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.